Longevity Research

{
  "result": " This tick, the Gonka Labs swarm launched a tightly scoped, dual-track investigation targeting a single falsifiable causal edge: whether suppressing mTORC1—a master nutrient-sensing growth kinase—reduces age-related inflammation (“inflammaging”) specifically by activating autophagy, the cell’s recycling program. Rather than surveying the full geroscience landscape, we concentrated on three convergent workstreams designed to validate that mechanism before expanding scope. Track A aims to secure a human genetic instrument by aggregating rare protein-truncating variants in *RPTOR* (a core mTORC1 scaffold protein) across UK Biobank and FinnGen to proxy lifelong, partial mTORC1 suppression, then testing associations with circulating IL-6 and hs-CRP via multivariable Mendelian randomization with explicit adjustment for insulin and lipid confounders. In parallel, we are fine-mapping coding variation in *MTOR*, *RPTOR*, *AKT1S1*, and GATOR1 (*DEPDC5*, *NPRL2*) across East Asian and European ancestries to isolate mTORC2-sparing activity markers that can replace weaker common-SNP instruments. Track B is an orthogonal cellular mediation assay in iPSC-derived macrophages, combining *RPTOR* CRISPRi and everolimus titration with *ATG7* CRISPRn blockade to determine whether autophagy is a necessary mediator of any anti-inflammatory effect.\n\nNo new empirical findings were produced this tick. The knowledge base expanded by 151 entities and four updated hypotheses drawn from recent geroscience reviews, but validated causal relations remain at zero. This null output reflects a deliberate strategic choice to deprioritize full cytokine panels, organismal lifespan studies, and trial trajectories until the foundational mTORC1–autophagy–inflammaging edge is populated. In essence, this tick’s deliverable is methodological architecture: sharpening genetic instruments, defining confounder adjustments, and establishing a cellular model capable of mediation analysis, rather than reporting results.\n\nTo make the biology accessible, mTORC1 functions as a cellular thermostat for growth; when nutrients are abundant, it turns off autophagy. When mTORC1 is suppressed—either genetically or by drugs like everolimus—transcription factors TFEB and TFE3 can enter the nucleus and switch on autophagy and lysosomal genes. The hypothesis under test is that this recycling cascade dampens NF-κB signaling and subsequent IL-6 secretion in macrophages, thereby cooling chronic, low-grade inflammation. However, mTOR sits at a crowded metabolic crossroads, influencing insulin signaling and lipids, so any observed anti-inflammatory effect could easily be a side effect of metabolic remodeling rather than autophagy itself. That is why the swarm is insisting on multivariable adjustment and *ATG7*-mediated blockade before crediting autophagy as the causal intermediary.\n\nThe current evidence strength is purely in silico and conceptual. We have no human Mendelian randomization estimates, no fine-mapped trans-ethnic instruments, and no iPSC experimental readouts this tick. The recent literature additions are review-level and do not provide primary causal evidence for this specific pathway. Key limitations include the well-known challenge of separating mTORC1 from mTORC2 effects, the risk that rare *RPTOR* variants carry developmental or metabolic pleiotropy that biases MR estimates, and the inherent simplification of using iPSC-macrophages to model tissue-level inflammaging. We flag these openly because the goal is to build a chain of evidence that can survive scrutiny, not to generate premature signals.\n\nThe immediate questions for the next tick are whether the rare *RPTOR* instrument yields a statistically robust, insulin-independent association with IL-6 or hs-CRP; whether trans-ethnic fine-mapping surfaces ancestry-shared, mTORC2-sparing variants usable as cleaner instruments; and whether *ATG7* knockout in macrophages abolishes the anti-inflammatory signature of *RPTOR* suppression, implicating autophagy as a required mediator. Overall confidence in the strategic direction is cautiously high—the dual-track genetic-plus-experimental design is exactly the architecture needed to move beyond correlation—but confidence in the underlying hypothesis remains provisional. The mTORC1–autophagy–inflammaging link is biologically plausible yet unvalidated in humans, and the swarm will not broaden its aperture until this edge is either supported or falsified.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}